Moneycontrol PRO
Open App
you are here: HomeNewsBusiness

Lupin gets USFDA nod for generic cancer treatment drug

The company in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets

August 29, 2022 / 04:36 PM IST
Lupin

Lupin

Lupin on Monday said it has received a tentative approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancer, in America.

The company in partnership with Pharmascience Inc. has received approval from the US Food and Drug Administration (FDA) for Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, it said in a statement.

The Mumbai-based drugmaker's product is a generic version of Bristol-Myers Squibb Company's Sprycel tablets. As per IQVIA MAT data, Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US.

Shares of Lupin settled at Rs 662.50 apiece, up 1.49 per cent on the BSE.
PTI
first published: Aug 29, 2022 04:36 pm
Sections
ISO 27001 - BSI Assurance Mark